Acta Veterinaria et Zootechnica Sinica ›› 2021, Vol. 52 ›› Issue (3): 809-819.doi: 10.11843/j.issn.0366-6964.2021.03.025

• CLINICAL VETERINARY MEDICINE • Previous Articles     Next Articles

A Study on Mechanism of Matrine against PRRSV Based on Network Pharmacology and Molecular Docking

HAO Jianghua1, SUN Na1, SUN Panpan2, SUN Yaogui1, FAN Kuohai2, YIN Wei1, LI Hongquan1*   

  1. 1. College of Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China;
    2. Laboratory Animal Center, Shanxi Agricultural University, Taigu 030801, China
  • Received:2020-09-14 Online:2021-03-23 Published:2021-03-24

Abstract: Based on network pharmacology and molecular docking technology, this study explored the anti-PRRSV mechanism of matrine from the perspective of anti-inflammatory. PharmMapper server and Genecards disease database were used to obtain the potential targets of matrine; STRING online analysis platform combined with Cytoscape software was used to construct the target protein-protein interaction (PPI) network and perform topological analysis to screen the key targets; DAVID database was used to perform gene ontology GO enrichment analysis and KEGG pathway enrichment analysis of the targets, and Cytoscape software was used to construct the "drug-target-pathway" network diagram; Autodock Vina software was used for molecular docking to select the best binding targets. The results of network analysis showed that there were 23 potential targets of matrine; the protein interaction network suggested that IGFⅠ, MAPK8, CASP3, and NR3C1 may be the core targets of matrine; 116 cell biological processes were obtained by GO enrichment analysis, and 47 related signaling pathways were obtained by KEGG pathway enrichment analysis; molecular docking showed that MAPK8 had a good affinity to matrine and maybe the main target of matrine exerting its effect. Matrine may play an anti-inflammatory role by acting on the key protein of MAPK8, thus achieving anti-PRRSV effect.

Key words: matrine, network pharmacology, anti-inflammatory, target

CLC Number: